新化股份(603867.SH):2020年度净利预增61.95%左右
格隆汇1月21日丨新化股份(603867.SH)披露2020年年度业绩预增公告,公司预计2020年度实现归属上市公司股东净利润为2亿元左右,与上年同期相比增加61.95%左右。扣除非经常性损益事项后,公司预计2020年度实现归属上市公司股东净利润为1.76亿元左右,与上年同期相比增加57.41%左右。本期业绩预增的主要原因如下:
(一)报告期内,公司克服疫情对公司产生的不良影响,紧抓市场机遇,公司产品异丙醇海外订单增加,销售价格上涨,促进了业绩增长。
(二)报告期内,公司积极推进江苏基地全面复产工作,落实2020年经营计划,2020年江苏基地营业收入、营业利润较上年实现大幅增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.